产品概述
| 产品名称（Product Name） | p27 (phospho Thr198) Rabbit Polyclonal Antibody |
| 描述（Description） | Rabbit Polyclonal Antibody |
| 宿主（Host） | Rabbit |
| 应用（Application） | WB,ELISA |
| 种属反应性（Reactivity） | Human,Rat,Mouse |
产品性能
| 偶联物（Conjugation） | Unconjugated |
| 修饰（Modification） | Phospho Antibody |
| 同种型（Isotype） | IgG |
| 克隆（Clonality） | Polyclonal |
| 形式（Form） | Liquid |
| 存放说明（Storage） | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| 储存溶液（Buffer） | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% New type preservative N. |
| 纯化方式（Purification） | Affinity purification |
免疫原
| 基因名（Gene Name） | CDKN1B |
| 别名（Alternative Names） | CDKN1B; KIP1; Cyclin-dependent kinase inhibitor 1B; Cyclin-dependent kinase inhibitor p27; p27Kip1 |
| 基因ID（Gene ID） | 1027 |
| 蛋白ID（SwissProt ID） | P46527 |
产品应用
| 稀释比（Dilution Ratio） | WB 1:500-1:2000, ELISA 1:20000.Not yet tested in other applications. |
| 蛋白分子量（Molecular Weight） | 27kDa |
研究背景
This gene encodes a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. The encoded protein binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controls the cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Mutations in this gene are associated with multiple endocrine neoplasia type IV (MEN4). [provided by RefSeq, Apr 2014],disease:Defects in CDKN1B are the cause of multiple endocrine neoplasia type 4 (MEN4) [MIM:610755]. Multiple endocrine neoplasia (MEN) syndromes are inherited cancer syndromes of the thyroid. MEN4 is a MEN-like syndrome with a phenotypic overlap of both MEN1 and MEN2.,domain:A peptide sequence containing only AA 28-79 retains substantial Kip1 cyclin A/CDK2 inhibitory activity.,function:Important regulator of cell cycle progrssion. Involved in G1 arrest. Potent inhibitor of cyclin E- and cyclin A-CDK2 complexes. Positive regulator of cyclin D-dependent kinases such as CDK4. Regulated by phosphorylation and degradation events.,induction:Maximal levels in quiescence cells and early G(1). Levels decrease after mitogen stimulation as cells progress toward S-phase.,miscellaneous:Decreased levels of p27Kip1, mainly due to proteosomal degradation, are found in various epithelial tumors originating from lung, breast, colon, ovary, esophagus, thyroid and prostate.,PTM:Phosphorylated; phosphorylation occurs on serine, threonine and tyrosine residues. Phosphorylation on Ser-10 is the major site of phosphorylation in resting cells, takes place at the G(0)-G(1) phase and leads to protein stability. Phosphorylation on other sites is greatly enhanced by mitogens, growth factors, cMYC and in certain cancer cell lines. The phosphorylated form found in the cytoplasm is inactivate. Phosphorylation on Thr-198 is required for interaction with 14-3-3 proteins. Phosphorylation on Thr-187, by CDK2 leads to protein ubiquitination and proteasomal degradation. Tyrosine phosphorylation promotes this process. Phosphorylation by PKB/AKT1 can be suppressed by LY294002, an inhibitor of the catalytic subunit of PI3K. Phosphorylation on Tyr-88 and Tyr-89 has no effect on binding CDK2, but is required for binding CDK4. Dephosphorylated on tyrosine residues by G-CSF.,PTM:Ubiquitinated; in the cytoplasm by the KPC1/KPC2 complex and, in the nucleus, by SCF/SKP2. The latter requires prior phosphorylation on Thr-187.,similarity:Belongs to the CDI family.,subcellular location:Nuclear and cytoplasmic in quiescent cells. AKT- or RSK-mediated phosphorylation on Thr-198, binds 14-3-3, translocates to the cytoplasm and promotes cell cycle progression. Mitogen-activated UHMK1 phosphorylation on Ser-10 also results in translocation to the cytoplasm and cell cycle progression. Phosphorylation on Ser-10 facilitates nuclear export. Translocates to the nucleus on phosphorylation of Tyr-88 and Tyr-89.,subunit:Interacts with NUP50; the interaction leads to nuclear import and degradation of phosphorylated p27kip1. Interacts with COPS5, subunit of the COP9 signalosome complex; the interaction leads to p27KIP degradation. Interacts with SPDYA in the SPDYA/CDK2/p27kip1 complex. Interacts (Thr-198 phosphorylated-form) with 14-3-3 proteins, binds strongly YWHAQ, weakly YWHAE and YWHAH, but not YWHAB nor YWHAZ; the interaction with YWHAQ results in translocation to the cytoplasm. Interacts with AKT1, LYN and UHMK1; the interactions lead to cytoplasmic mislocation, phosphorylation of p27kip1 and inhibition of cell cycle arrest. Interacts (unphosphorylated form) with CDK2. Interacts (phosphorylated on Tyr-88 and Tyr-89) with CDK4; the interaction induces nuclear translocation. Interacts with GRB2.,tissue specificity:Expressed in all tissues tested. Highest levels in skeletal muscle, lowest in liver and kidney.,
研究领域
ErbB_HER;Cell_Cycle_G1S;Cell_Cycle_G2M_DNA;Pathways in cancer;Prostate cancer;Chronic myeloid leukemia;Small cell lung cancer;
关键字： CDKN1B;p27;(phospho;Thr198);Rabbit;Polyclonal;Antibody;一抗
武汉恩玑生命科技有限公司（EnkiLife）是一家深耕生命科学，专注细胞生物学和免疫学科研试剂的研发、生产与销售的生物技术企业，在全球100多个国家和地区开展业务，致力于为科研工作者提供高质量的产品和卓越的客户服务，推动生命科学的发展。
EnkiLife的产品线涵盖细胞系、原代细胞、细胞培养基、血清、细胞检测试剂盒、重组靶点蛋白、细胞因子、重组抗体、ELISA试剂盒、生化试剂盒等，并提供技术服务与定制开发，覆盖了生命科学研究的各大关键领域，包括细胞生物学、癌症、免疫学、神经科学、心血管疾病、干细胞、表观遗传学、内分泌、蛋白质组学、代谢组学等，全方位满足您的实验需求，让您享受科研的乐趣！
公司现已建立四大技术平台：
EnCyto?细胞培养及检测平台：拥有细胞系库（500+）、原代细胞库（500+）、基础培养基和完全培养基（1200+）
EnkiPro?重组蛋白平台：现货产品2000+，可提供定制化表达服务
EnAb?重组抗体平台：重组兔单抗（3000+），可提供定制化和标记服务
EnKits?试剂盒开发平台：可提供优质的ELISA试剂盒、配套试剂、抗体对、生化试剂盒等相关产品
EnkiLife在生产管理方面引入ISO9001质量管理体系和信息化、自动化的管理工具，拥有高效稳定的交付能力，与全球知名品牌建立了紧密的合作。
EnkiLife始终坚持以技术创新为驱动，以匠心铸就品质，以品质服务客户。
我们期待与更多的全球科研工作者和企业携手合作，共同推动生命科学领域的进步与发展。